NASDAQ:AERI - Aerie Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.08
  • Forecasted Upside: 48.82 %
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.02 (-0.13%)

This chart shows the closing price for AERI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aerie Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AERI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AERI

Analyst Price Target is $23.08
▲ +48.82% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Aerie Pharmaceuticals in the last 3 months. The average price target is $23.08, with a high forecast of $32.00 and a low forecast of $9.00. The average price target represents a 48.82% upside from the last price of $15.51.

This chart shows the closing price for AERI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Aerie Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/23/2021Needham & Company LLCInitiated CoverageBuy$26.00N/A
7/22/2021MizuhoReiterated RatingBuy$28.00High
7/16/2021Needham & Company LLCInitiated CoverageBuy$26.00Medium
7/13/2021Raymond JamesSet Price Target$15.65Low
7/12/2021Raymond JamesReiterated RatingHoldLow
7/9/2021Needham & Company LLCInitiated CoverageBuy$26.00Low
7/2/2021Needham & Company LLCInitiated CoverageBuy$26.00Low
4/30/2021Needham & Company LLCInitiated CoverageBuy$26.00Medium
4/23/2021Needham & Company LLCInitiated CoverageBuy$26.00Medium
3/1/2021HC WainwrightReiterated RatingBuyHigh
2/5/2021Needham & Company LLCInitiated CoverageBuy$26.00Low
12/28/2020MizuhoReiterated RatingBuy$28.00N/A
12/28/2020Needham & Company LLCReiterated RatingBuy$26.00N/A
11/9/2020HC WainwrightLower Price TargetBuy$31.00 ➝ $29.00High
11/6/2020MizuhoReiterated RatingBuyHigh
10/19/2020Bank of AmericaDowngradeNeutral ➝ Underperform$14.00 ➝ $9.00High
10/5/2020Raymond JamesReiterated RatingHoldHigh
10/5/2020Needham & Company LLCReiterated RatingBuy$26.00Medium
9/28/2020Raymond JamesReiterated RatingHoldMedium
9/8/2020Raymond JamesReiterated RatingHoldMedium
9/8/2020GuggenheimInitiated CoverageBuy$20.00Medium
8/24/2020Raymond JamesReiterated RatingHoldMedium
8/14/2020Needham & Company LLCInitiated CoverageBuy$26.00Low
8/10/2020CitigroupLower Price TargetBuy$38.00 ➝ $32.00Low
8/7/2020Piper SandlerLower Price Target$35.00 ➝ $25.00Low
8/7/2020MizuhoBoost Price TargetBuy$27.00 ➝ $29.00High
8/7/2020Needham & Company LLCLower Price TargetBuy$32.00 ➝ $26.00High
7/28/2020MizuhoReiterated RatingBuy$29.00Low
7/24/2020Needham & Company LLCInitiated CoverageBuy$32.00Medium
7/6/2020Needham & Company LLCInitiated CoverageBuy$38.00High
6/26/2020Needham & Company LLCInitiated CoverageBuy$38.00Low
6/19/2020Needham & Company LLCInitiated CoverageBuy$38.00Medium
6/12/2020Needham & Company LLCInitiated CoverageBuy$38.00Low
6/5/2020Needham & Company LLCInitiated CoverageBuy$38.00High
5/29/2020OppenheimerInitiated CoverageBuy$22.00 ➝ $24.00High
5/29/2020Needham & Company LLCInitiated CoverageBuy$38.00High
5/22/2020Needham & Company LLCInitiated CoverageBuy$38.00N/A
5/7/2020SunTrust BanksLower Price TargetBuy$26.00 ➝ $22.00Medium
5/7/2020Needham & Company LLCReiterated RatingBuyHigh
5/7/2020MizuhoLower Price TargetBuy$34.00 ➝ $29.00High
5/7/2020Piper SandlerLower Price TargetOverweight$45.00 ➝ $35.00High
5/7/2020HC WainwrightLower Price TargetBuy$37.00 ➝ $31.00High
4/30/2020Needham & Company LLCLower Price TargetBuy$40.00 ➝ $38.00Low
4/24/2020Needham & Company LLCReiterated RatingBuy$40.00Medium
4/13/2020MizuhoLower Price TargetBuy$54.00 ➝ $34.00Medium
4/13/2020OppenheimerLower Price TargetOutperform$28.00 ➝ $26.00Low
4/13/2020Needham & Company LLCReiterated RatingBuy$40.00Low
4/1/2020Stifel NicolausLower Price TargetBuy$45.00 ➝ $40.00Medium
3/27/2020Needham & Company LLCReiterated RatingBuy$40.00High
3/23/2020Bank of AmericaLower Price TargetNeutral$26.00 ➝ $17.00Low
3/23/2020Bank of AmericaReiterated RatingHold$17.00Low
2/28/2020MizuhoReiterated RatingBuyMedium
2/21/2020HC WainwrightLower Price TargetBuy$41.00 ➝ $37.00High
2/21/2020JMP SecuritiesReiterated RatingOutperform ➝ Average$35.00High
2/16/2020Needham & Company LLCReiterated RatingBuy$40.00High
2/13/2020Piper SandlerLower Price Target$48.00 ➝ $45.00Low
1/10/2020Bank of AmericaInitiated CoverageNeutral$27.00High
1/9/2020SunTrust BanksInitiated CoverageBuy$32.00High
12/30/2019Needham & Company LLCReiterated RatingBuy$40.00High
12/20/2019MizuhoReiterated RatingBuy$54.00High
12/19/2019CitigroupInitiated CoverageBuy$36.00High
12/6/2019Needham & Company LLCInitiated CoverageBuy$40.00Low
12/5/2019MizuhoReiterated RatingBuy$54.00High
11/29/2019Needham & Company LLCReiterated RatingBuy$40.00Low
11/18/2019Needham & Company LLCReiterated RatingBuy$40.00Low
11/7/2019OppenheimerLower Price Target$45.00 ➝ $25.00High
11/7/2019JMP SecuritiesLower Price TargetOutperform$41.00High
11/7/2019Stifel NicolausLower Price TargetBuy$77.00 ➝ $45.00High
11/7/2019CowenReiterated RatingOutperform$105.00 ➝ $50.00High
11/7/2019HC WainwrightLower Price TargetBuy$55.00 ➝ $41.00High
11/7/2019Cantor FitzgeraldLower Price TargetOverweight$62.00 ➝ $30.00High
11/7/2019MizuhoReiterated RatingBuy$63.00 ➝ $54.00High
10/25/2019Needham & Company LLCReiterated RatingBuy$54.00Low
10/24/2019HC WainwrightReiterated RatingBuyHigh
10/18/2019MizuhoSet Price TargetBuy$63.00High
10/18/2019Needham & Company LLCSet Price TargetBuy$54.00High
10/15/2019Piper Jaffray CompaniesReiterated RatingBuyLow
10/11/2019MizuhoSet Price TargetBuy$63.00Low
10/11/2019Needham & Company LLCSet Price TargetBuy$54.00Low
10/4/2019Needham & Company LLCReiterated RatingBuy$54.00Low
9/27/2019Needham & Company LLCSet Price TargetBuy$54.00Low
9/27/2019MizuhoSet Price TargetBuy$63.00Low
9/13/2019MizuhoSet Price TargetBuy$63.00High
8/16/2019MizuhoSet Price TargetBuy$63.00High
8/8/2019HC WainwrightReiterated RatingBuy$57.00High
8/8/2019CitigroupReiterated RatingOutperform$65.00 ➝ $45.00High
8/8/2019JMP SecuritiesLower Price TargetMarket Outperform$58.00 ➝ $52.00High
8/8/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$74.00 ➝ $54.00High
8/8/2019Piper Jaffray CompaniesLower Price TargetOverweight$76.00 ➝ $53.00High
8/8/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$85.00 ➝ $62.00High
8/2/2019MizuhoSet Price TargetBuy$77.00Medium
7/24/2019HC WainwrightReiterated RatingBuy$57.00High
7/19/2019MizuhoSet Price TargetBuy$77.00N/A
7/10/2019Needham & Company LLCReiterated RatingBuy ➝ Positive$74.00Low
7/5/2019Piper Jaffray CompaniesSet Price TargetBuy$76.00Low
7/2/2019JMP SecuritiesSet Price TargetAverage ➝ Outperform$75.00 ➝ $58.00High
6/11/2019Canaccord GenuitySet Price TargetBuy$56.00High
5/10/2019Canaccord GenuityLower Price TargetBuy$65.00 ➝ $56.00Low
5/8/2019Piper Jaffray CompaniesSet Price TargetBuy$76.00High
4/21/2019MizuhoReiterated RatingBuy$77.00Medium
3/21/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$80.00 ➝ $80.00High
3/19/2019OppenheimerReiterated RatingBuyLow
3/19/2019Canaccord GenuitySet Price TargetBuy$73.00 ➝ $65.00Medium
3/13/2019MizuhoReiterated RatingBuy$77.00High
3/5/2019Canaccord GenuityLower Price TargetBuy$86.00 ➝ $73.00Low
2/27/2019CowenReiterated RatingBuyLow
2/26/2019HC WainwrightReiterated RatingBuyMedium
2/26/2019Cantor FitzgeraldSet Price TargetBuy$85.00Low
2/26/2019OppenheimerSet Price TargetBuy$64.00Low
2/8/2019MizuhoReiterated RatingBuyHigh
1/18/2019MizuhoReiterated RatingBuy$77.00High
12/20/2018Canaccord GenuitySet Price TargetBuy$65.00Low
12/3/2018OppenheimerInitiated CoverageBuy$64.00Medium
11/27/2018MizuhoReiterated RatingBuy$77.00High
11/12/2018FIXInitiated CoverageOutperform ➝ Reduce$64.00Medium
11/12/2018OppenheimerInitiated CoverageBuy$64.00Medium
11/7/2018MizuhoReiterated RatingBuy$77.00High
11/6/2018CowenSet Price TargetBuy$105.00High
10/10/2018JMP SecuritiesSet Price TargetBuy$80.00High
10/2/2018Cantor FitzgeraldReiterated RatingBuy$86.00High
9/11/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$80.00 ➝ $87.00Medium
8/10/2018Canaccord GenuityReiterated RatingBuy$86.00Low
8/9/2018CowenBoost Price TargetBuy$100.00 ➝ $105.00Low
8/9/2018HC WainwrightSet Price TargetBuy$78.00Medium
7/13/2018Needham & Company LLCSet Price TargetBuy$76.00 ➝ $86.00Low
6/5/2018Canaccord GenuitySet Price TargetBuy$86.00High
6/1/2018MizuhoReiterated RatingBuy$77.00High
5/15/2018Canaccord GenuitySet Price TargetBuy$86.00Low
5/9/2018HC WainwrightSet Price TargetBuy$78.00Low
5/9/2018MizuhoReiterated RatingBuy$77.00Low
5/8/2018Canaccord GenuitySet Price TargetBuy$86.00Low
5/8/2018Cantor FitzgeraldSet Price TargetBuy$86.00Low
5/1/2018MizuhoLower Price TargetBuy$77.00Medium
3/29/2018MizuhoSet Price TargetBuy$87.00Low
3/5/2018Seaport Global SecuritiesReiterated RatingBuyMedium
3/1/2018HC WainwrightSet Price TargetBuy$78.00High
2/28/2018Cantor FitzgeraldSet Price TargetBuy$86.00High
2/16/2018HC WainwrightInitiated CoverageBuy ➝ Buy$78.00Medium
1/29/2018MizuhoReiterated RatingBuy$87.00Low
1/26/2018Seaport Global SecuritiesInitiated CoverageBuy ➝ Buy$78.00Low
1/25/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$73.00 ➝ $86.00Medium
12/19/2017MizuhoReiterated RatingBuy$87.00Low
12/18/2017Canaccord GenuitySet Price TargetBuy$73.00High
12/18/2017Cantor FitzgeraldSet Price TargetBuy$77.00High
11/16/2017Canaccord GenuitySet Price TargetBuy$73.00N/A
11/16/2017Cantor FitzgeraldSet Price TargetBuy$69.00N/A
11/9/2017MizuhoReiterated RatingBuy$87.00N/A
11/3/2017MizuhoReiterated RatingBuyN/A
10/25/2017MizuhoReiterated RatingBuy$70.00N/A
10/23/2017GuggenheimInitiated CoverageBuy$80.00N/A
10/16/2017Canaccord GenuityReiterated RatingBuy ➝ Positive$65.00 ➝ $73.00N/A
10/16/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$65.00 ➝ $76.00N/A
10/16/2017MizuhoReiterated RatingBuy$70.00N/A
10/11/2017JMP SecuritiesSet Price TargetBuy$68.00N/A
10/11/2017Canaccord GenuitySet Price TargetBuy$65.00N/A
10/11/2017Cantor FitzgeraldReiterated RatingPositive ➝ Buy$62.00N/A
10/5/2017CowenReiterated RatingBuyN/A
10/2/2017MizuhoReiterated RatingBuy$70.00High
9/22/2017Canaccord GenuityReiterated RatingBuyLow
9/20/2017MizuhoReiterated RatingBuy$70.00High
9/17/2017Needham & Company LLCReiterated RatingBuy$65.00High
9/6/2017MizuhoInitiated CoverageBuy$70.00Medium
8/16/2017Canaccord GenuitySet Price TargetBuy$65.00High
8/8/2017Canaccord GenuitySet Price TargetBuy$65.00Low
8/2/2017HC WainwrightSet Price TargetBuy$69.00High
8/1/2017Canaccord GenuitySet Price TargetBuy$65.00High
7/28/2017Stifel NicolausReiterated RatingBuy$70.00Medium
7/20/2017Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$56.00 ➝ $62.00High
7/4/2017Stifel NicolausBoost Price TargetBuy$55.00 ➝ $65.00Medium
7/3/2017Canaccord GenuityReiterated RatingBuy$65.00Medium
5/26/2017Stifel NicolausReiterated RatingBuyN/A
5/26/2017CowenSet Price TargetBuy$100.00N/A
5/25/2017AegisBoost Price TargetBuy$63.00 ➝ $70.00High
5/25/2017HC WainwrightReiterated RatingBuy$69.00High
5/25/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$58.00 ➝ $65.00High
5/24/2017Cantor FitzgeraldSet Price TargetBuy$56.00High
5/22/2017Canaccord GenuitySet Price TargetBuy$56.00Low
5/3/2017HC WainwrightReiterated RatingBuy$69.00High
4/24/2017Needham & Company LLCReiterated RatingBuy$58.00Low
4/18/2017Canaccord GenuityReiterated RatingBuy$56.00Medium
4/18/2017CowenReiterated RatingOutperform$70.00Medium
4/18/2017Cantor FitzgeraldReiterated RatingOverweight$56.00Medium
4/18/2017Stifel NicolausReiterated RatingBuy$65.00Low
4/15/2017HC WainwrightSet Price TargetBuy$69.00Low
4/13/2017AegisReiterated RatingBuy$63.00High
4/12/2017Cantor FitzgeraldSet Price TargetBuy$56.00Medium
4/6/2017Stifel NicolausBoost Price TargetBuy$55.00 ➝ $65.00Medium
3/31/2017JMP SecuritiesReiterated RatingOutperform$57.00Low
3/11/2017Canaccord GenuitySet Price TargetBuy$56.00Low
3/9/2017Raymond JamesDowngradeStrong-Buy ➝ Market Perform$48.00Low
3/8/2017AegisReiterated RatingBuy ➝ In-Line$63.00High
3/8/2017Royal Bank of CanadaBoost Price TargetOutperform$54.00 ➝ $55.00Medium
3/8/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$52.00 ➝ $58.00Medium
3/8/2017Cantor FitzgeraldBoost Price TargetOverweight$50.00 ➝ $56.00Medium
3/8/2017Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$54.00 ➝ $55.00Medium
3/1/2017Canaccord GenuitySet Price TargetBuy$50.00N/A
2/24/2017CowenInitiated CoverageOutperform$70.00N/A
2/17/2017Roth CapitalInitiated CoverageBuy$69.00N/A
12/28/2016Needham & Company LLCReiterated RatingBuy$52.00N/A
12/23/2016JMP SecuritiesReiterated RatingOutperform$49.00N/A
12/20/2016Canaccord GenuityReiterated RatingBuy$50.00N/A
11/10/2016AegisReiterated RatingBuy$63.00N/A
11/1/2016AegisInitiated CoverageBuy$63.00N/A
10/28/2016Royal Bank of CanadaBoost Price TargetOutperform$48.00 ➝ $49.00N/A
10/21/2016Royal Bank of CanadaReiterated RatingOutperform$55.00N/A
10/8/2016Cantor FitzgeraldReiterated RatingBuy$50.00N/A
10/6/2016Stifel NicolausBoost Price TargetBuy$50.00 ➝ $55.00N/A
10/6/2016Brean CapitalReiterated RatingBuy$48.00 ➝ $63.00N/A
9/29/2016Brean CapitalSet Price TargetBuy$48.00N/A
9/20/2016HC WainwrightInitiated CoverageBuy$66.00N/A
9/16/2016Royal Bank of CanadaReiterated RatingOutperform$51.00 ➝ $55.00N/A
9/15/2016Brean CapitalSet Price TargetBuy$48.00N/A
9/15/2016Stifel NicolausBoost Price TargetBuy$40.00 ➝ $50.00N/A
9/15/2016Needham & Company LLCReiterated RatingBuy$45.00 ➝ $52.00N/A
9/15/2016Cantor FitzgeraldBoost Price TargetBuy$44.00 ➝ $50.00N/A
9/15/2016Royal Bank of CanadaBoost Price TargetOutperform$51.00 ➝ $55.00N/A
9/14/2016Canaccord GenuitySet Price TargetBuy$44.00 ➝ $50.00N/A
9/13/2016Raymond JamesInitiated CoverageOutperform$48.00N/A
9/7/2016Brean CapitalReiterated RatingBuy$48.00N/A
8/23/2016Needham & Company LLCReiterated RatingBuy$45.00N/A
(Data available from 7/25/2016 forward)
Aerie Pharmaceuticals logo
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $15.51
Low: $15.28
High: $15.85

50 Day Range

MA: $16.30
Low: $15.16
High: $18.84

52 Week Range

Now: $15.51
Low: $9.01
High: $21.30


233,515 shs

Average Volume

450,143 shs

Market Capitalization

$727.26 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Aerie Pharmaceuticals?

The following Wall Street analysts have issued research reports on Aerie Pharmaceuticals in the last twelve months: Bank of America Co., Citigroup Inc., Guggenheim, HC Wainwright, Mizuho, Needham & Company LLC, Piper Sandler, Raymond James, and Zacks Investment Research.
View the latest analyst ratings for AERI.

What is the current price target for Aerie Pharmaceuticals?

8 Wall Street analysts have set twelve-month price targets for Aerie Pharmaceuticals in the last year. Their average twelve-month price target is $23.08, suggesting a possible upside of 48.8%. Citigroup Inc. has the highest price target set, predicting AERI will reach $32.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $9.00 for Aerie Pharmaceuticals in the next year.
View the latest price targets for AERI.

What is the current consensus analyst rating for Aerie Pharmaceuticals?

Aerie Pharmaceuticals currently has 1 sell rating, 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AERI will outperform the market and that investors should add to their positions of Aerie Pharmaceuticals.
View the latest ratings for AERI.

What other companies compete with Aerie Pharmaceuticals?

How do I contact Aerie Pharmaceuticals' investor relations team?

Aerie Pharmaceuticals' physical mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company's listed phone number is 919-237-5300 and its investor relations email address is [email protected] The official website for Aerie Pharmaceuticals is